Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclopofol + sufentanil effective dose for painless gastrointestinal endoscopy by age and gender
ChiCTR2400089147Phase 4Not yet recruiting
- Sponsor
- Huludao Central Hospital
- Start
- Sep 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ciprofol in None (6 arms), sponsored by Huludao Central Hospital. Primary endpoints: ED50 of cyclopofol dose for painless gastrointestinal endoscopy and ED95 of cyclopofol dose for painless gastrointestinal endoscopy. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ciprofol
Beyond the preview
Go deeper on ChiCTR2400089147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089147.